A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1239-1245

  Pallis, Athanasios G ^a   Chandrinos, Vassilis ^b   Pavlakou, Georgia ^c   Xenidis, Nikolaos ^d   Varthalitis, Ioannis ^e   Vardakis, Nikolaos ^a   Vamvakas, Lambros ^a   Kontopodis, Emmanouel ^a   Rovithi, Maria ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^e Department of Medical Oncology   (Greece)

Author keywords

Cisplatin; Dose limiting toxicities; Maximum tolerated doses; Metronomic; NSCLC; Oral Vinorelbine; Phase I

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DOSE LIMITING TOXICITY; DRUG DOSE ESCALATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 79959615397     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1415-9     Document Type: Article

References (31)

1. Goa KL, Faulds D (1994) Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5:200-234
2. Potier P (1989) The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16:2-4
3. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649 (Pubitemid 34070598)
4. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O'Brien M, Puozzo C (2007) Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67:1403-1410 (Pubitemid 47026390)
5. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, Depierr A (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-smallcell lung cancer patients. Ann Oncol 12:1375-1381 (Pubitemid 33100241)
6. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047 (Pubitemid 30217688)
7. Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12-15 (Pubitemid 34436715)
8. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436 (Pubitemid 38745528)
9. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454-6461
10. (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ 311:899-909
11. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. J Clin Oncol 27(36):6251-6266
12. Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne PL, Seebacher C, Grivaux M, Ojala A, Aubert D, Lefresne F (2003) Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14:1634-1639 (Pubitemid 37455812)
13. Chen YM, Yu CJ, Yang CH, Perng RP, Tsai CM, Shih JF, Cheng AL, Lefresne F, Barbier M, Pouget JC, Yang PC (2007) A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 56:89-95 (Pubitemid 46356641)
14. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La PM, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di BM, Giorgi G, Gotti G, Francini G (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16:133-140
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655 (Pubitemid 13149996)
16. ICH Efficacy Guidelines.E6(R1) (2009) Good clinical practice: consolidated guideline. http://www.ich.org/cache/compo/475-272-1.html
17. Cancer Therapy Evaluation Program (1998) Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI Cancer Spectr 92:205-216 (Pubitemid 30099779)
19. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938-6943 (Pubitemid 35424084)
20. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32:1065-1073 (Pubitemid 19237859)
21. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V (2003) Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408-8413 (Pubitemid 37549496)
22. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643-1648 (Pubitemid 37238620)
23. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232-238 (Pubitemid 43160111)
24. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623-3628 (Pubitemid 46630536)
25. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594-2601
26. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G (2006) Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42:2821-2832 (Pubitemid 44584664)
27. Douillard JY, Rosell R, De LM, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le GA, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-smallcell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719-727 (Pubitemid 44283661)
28. Arriagada R, Bergman B, Dunant A, Le CT, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360 (Pubitemid 38101630)
29. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced nonsmall- cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945 (Pubitemid 46224112)
30. Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, De Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
31. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R (2009) Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 20:1249-1256